|
1
|
Bishop GA: The multifaceted roles of TRAFs
in the regulation of B-cell function. Nat Rev Immunol. 4:775–786.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pellat-Deceunynck C, Bataille R, Robillard
N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J and Amiot M:
Expression of CD28 and CD40 in human myeloma cells: A comparative
study with normal plasma cells. Blood. 84:2597–2603.
1994.PubMed/NCBI
|
|
3
|
Westendorf JJ, Ahmann GJ, Armitage RJ,
Spriggs MK, Lust JA, Greipp PR, Katzmann JA and Jelinek DF: CD40
expression in malignant plasma cells. Role in stimulation of
autocrine IL-6 secretion by a human myeloma cell line. J Immunol.
152:117–128. 1994.PubMed/NCBI
|
|
4
|
Uckun FM, Gajl-Peczalska K, Myers DE,
Jaszcz W, Haissig S and Ledbetter JA: Temporal association of CD40
antigen expression with discrete stages of human B-cell ontogeny
and the efficacy of anti-CD40 immunotoxins against clonogenic
B-lineage acute lymphoblastic leukemia as well as B-lineage
non-Hodgkin's lymphoma cells. Blood. 76:2449–2456. 1990.PubMed/NCBI
|
|
5
|
O'Grady JT, Stewart S, Lowrey J, Howie SE
and Krajewski AS: CD40 expression in Hodgkin's disease. Am J
Pathol. 144:21–26. 1994.PubMed/NCBI
|
|
6
|
van Kooten C and Banchereau J: CD40-CD40
ligand. J Leukoc Biol. 67:2–17. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Banchereau J, Bazan F, Blanchard D, Brière
F, Galizzi JP, van Kooten C, Liu YJ, Rousset F and Saeland S: The
CD40 antigen and its ligand. Annu Rev Immunol. 12:881–922. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Law CL, Gordon KA, Collier J, Klussman K,
McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, et
al: Preclinical antilymphoma activity of a humanized anti-CD40
monoclonal antibody, SGN-40. Cancer Res. 65:8331–8338. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Costello RT, Gastaut JA and Olive D: What
is the real role of CD40 in cancer immunotherapy? Immunol Today.
20:488–493. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baltz KM, Krusch M, Bringmann A, Brossart
P, Mayer F, Kloss M, Baessler T, Kumbier I, Peterfi A, Kupka S, et
al: Cancer immunoediting by GITR (glucocorticoid-induced
TNF-related protein) ligand in humans: NK cell/tumor cell
interactions. FASEB J. 21:2442–2454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baessler T, Krusch M, Schmiedel BJ, Kloss
M, Baltz KM, Wacker A, Schmetzer HM and Salih HR:
Glucocorticoid-induced tumor necrosis factor receptor-related
protein ligand subverts immunosurveillance of acute myeloid
leukemia in humans. Cancer Res. 69:1037–1045. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Buechele C, Baessler T, Wirths S, Schmohl
JU, Schmiedel BJ and Salih HR: Glucocorticoid-induced TNFR-related
protein (GITR) ligand modulates cytokine release and NK cell
reactivity in chronic lymphocytic leukemia (CLL). Leukemia.
26:991–1000. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schmidt-Wolf IG, Lefterova P, Mehta BA,
Fernandez LP, Huhn D, Blume KG, Weissman IL and Negrin RS:
Phenotypic characterization and identification of effector cells
involved in tumor cell recognition of cytokine-induced killer
cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
|
|
14
|
Nwangwu CA, Weiher H and Schmidt-Wolf IGH:
Increase of CIK cell efficacy by upregulating cell surface MICA and
inhibition of NKG2D ligand shedding in multiple myeloma. Hematol
Oncol. 35:2016.PubMed/NCBI
|
|
15
|
He JY, Jia ZX, Cai XH, Han WM, Xiao R, Ma
LD, Lu XZ, Zhou M and Chen BA: Roles of NKG2D in cytokine-induced
killer (CIK) against hematological malignant cells lines. Zhongguo
Shi Yan Xue Ye Xue Za Zhi. 21:1380–1384. 2013.(In Chinese).
PubMed/NCBI
|
|
16
|
Verneris MR, Karimi M, Baker J, Jayaswal A
and Negrin RS: Role of NKG2D signaling in the cytotoxicity of
activated and expanded CD8+ T cells. Blood. 103:3065–3072. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao H, Fan Y, Li H, Yu J, Liu L, Cao S,
Ren B, Yan F and Ren X: Immunotherapy with cytokine-induced killer
cells as an adjuvant treatment for advanced gastric carcinoma: A
retrospective study of 165 patients. Cancer Biother Radiopharm.
28:303–309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hao MZ, Lin HL, Chen Q, Ye YB, Chen QZ and
Chen MS: Efficacy of transcatheter arterial chemoembolization
combined with cytokine-induced killer cell therapy on
hepatocellular carcinoma: A comparative study. Chin J Cancer.
29:172–177. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang B, Lu XC, Yu RL, Chi XH, Liu Y, Wang
Y, Dai HR, Zhu HL, Cai LL and Han WD: Repeated transfusions of
autologous cytokine-induced killer cells for treatment of
haematological malignancies in elderly patients: A pilot clinical
trial. Hematol Oncol. 30:115–122. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schmeel LC, Schmeel FC, Coch C and
Schmidt-Wolf IG: Cytokine-induced killer (CIK) cells in cancer
immunotherapy: Report of the international registry on CIK cells
(IRCC). J Cancer Res Clin Oncol. 141:839–849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Xu Z, Zhou F, Sun Y, Chen J, Li L,
Jin H and Qian Q: The combination of dendritic cells-cytotoxic T
lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts
immune and clinical responses in patients with malignant tumors.
Exp Hematol Oncol. 4:322015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Z, Liu Y, Li R, Shang Y, Zhang Y,
Zhao L, Li W, Yang Y, Zhang X, Yang T, et al: Autologous
cytokine-induced killer cell transfusion increases overall survival
in advanced pancreatic cancer. J Hematol Oncol. 9:62016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jäkel CE and Schmidt-Wolf IG: An update on
new adoptive immunotherapy strategies for solid tumors with
cytokine-induced killer cells. Expert Opin Biol Ther. 14:905–916.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jäkel CE, Vogt A, Gonzalez-Carmona MA and
Schmidt-Wolf IG: Clinical studies applying cytokine-induced killer
cells for the treatment of gastrointestinal tumors. J Immunol Res.
2014:8972142014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume
KG and Weissman IL: Use of a SCID mouse/human lymphoma model to
evaluate cytokine-induced killer cells with potent antitumor cell
activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cappuzzello E, Tosi A, Zanovello P,
Sommaggio R and Rosato A: Retargeting cytokine-induced killer cell
activity by CD16 engagement with clinical-grade antibodies.
Oncoimmunology. 5:e11993112016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hassan SB, Sørensen JF, Olsen BN and
Pedersen AE: Anti-CD40-mediated cancer immunotherapy: An update of
recent and ongoing clinical trials. Immunopharmacol Immunotoxicol.
36:96–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Szocinski JL, Khaled AR, Hixon J,
Halverson D, Funakoshi S, Fanslow WC, Boyd A, Taub DD, Durum SK,
Siegall CB, et al: Activation-induced cell death of aggressive
histology lymphomas by CD40 stimulation: Induction of bax. Blood.
100:217–223. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brady HJM and Gil-Gómez G: Molecules in
focus Bax. The pro-apoptotic Bcl-2 family member, Bax. Int J Bio
Cell Biol. 30:647–650. 1998. View Article : Google Scholar
|
|
30
|
Martin S, Pahari S, Sudan R and Saha B:
CD40 signaling in CD8+CD40+ T cells turns on contra-T regulatory
cell functions. J Immunol. 184:5510–5518. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McWhirter SM, Pullen SS, Holton JM, Crute
JJ, Kehry MR and Alber T: Crystallographic analysis of CD40
recognition and signaling by human TRAF2. Proc Natl Acad Sci USA.
96:8408–8413. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tsukamoto N, Kobayashi N, Azuma S,
Yamamoto T and Inoue J: Two differently regulated nuclear factor
kappaB activation pathways triggered by the cytoplasmic tail of
CD40. Proc Natl Acad Sci USA. 96:1234–1239. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Esparza EM and Arch RH:
Glucocorticoid-induced TNF receptor, a costimulatory receptor on
naive and activated T cells, uses TNF receptor-associated factor 2
in a novel fashion as an inhibitor of NF-kappa B activation. J
Immunol. 174:7875–7882. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Melero I, Grimaldi AM, Perez-Gracia JL and
Ascierto PA: Clinical development of immunostimulatory monoclonal
antibodies and opportunities for combination. Clin Cancer Res.
19:997–1008. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu BQ, Ju SW and Shu YQ: CD137 enhances
cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce
CD4(+) Th1 responses. Biomed Pharmacother. 63:509–516. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Esser L, Weiher H and Schmidt-Wolf I:
Increased efficacy of brentuximab vedotin (SGN-35) in combination
with cytokine-induced killer cells in lymphoma. Int J Mol Sci.
17(pii): E10562016. View Article : Google Scholar : PubMed/NCBI
|
